Publications

Showing 2 of 2 Publications

2021

Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data
Martini A, Parikh A, Sfakianos J, Montorsi F, Galsky M, Oh W, Tsao C. Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data. Prostate Cancer And Prostatic Diseases 2021, 24: 743-749. PMID: 33531652, DOI: 10.1038/s41391-021-00326-3.
Peer-Reviewed Original Research
MeSH Keywords and Concepts

2020

Predicting toxicity-related docetaxel discontinuation and survival in metastatic castration-resistant prostate cancer (mCRPC) using open phase III trial data.
Parikh A, Martini A, Sfakianos J, Galsky M, Oh W, Tsao C. Predicting toxicity-related docetaxel discontinuation and survival in metastatic castration-resistant prostate cancer (mCRPC) using open phase III trial data. Journal Of Clinical Oncology 2020, 38: 75-75. DOI: 10.1200/jco.2020.38.6_suppl.75.
Peer-Reviewed Original Research
Concepts

This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply